1. Haque A, Anudeep BP. Efforts at COVID-19 Vaccine Development: Challenges dan Successes. Vaccines 2020, 8, 739; doi:10.3390/vaccines8040739
2. Amant, F.; Krammer, F. SARS-CoV-2 Vaccines: Status Report. Immunity 2020, 52, 583–589
3. Gao Q, Bao L, Mao H, Wang L, Qin C. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020: 369: 77–81.
4. Zhang Y et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:181-92. DOI: https://doi.org/10.1016/ S1473-3099(20)30843-4
5. Sekretariat Kabinet Republik Indonesia. BPOM Berikan Persetujuan Penggunaan Vaksin COVID-19 produksi Sinovac. Available from URL: https://setkab.go.id/bpom-berikan-persetujuan-penggunaan-vaksin-covid-19-produksi-sinovac/
6. Channel News Asia. Turkey approves China-based Sinovac COVID-19 vaccine’s emergency use. Available from URL: https://www.channelnewsasia.com/news/world/turkey-approves-china-based-sinovac-covid-19-vaccine-s-emergency-13954284
7. Jeff craven. COVID-19 vaccine tracker. Available from URL: https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
8. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467–78.
9. Ramasamy M, Minassian AM. Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine administered in a prime boost regimen in older adults (COV002): a phase 2/3 single blind, randomised controlled trial. Lancet 2020; published online Nov 18. https://doi.org/10·1016/S0140–6736(20)32466–1
10. Barret JR, Belij-Rammerstorfer S. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med (in press).
11. Voysey et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99–111. https://doi.org/10.1016/ S0140-6736(20)32661-1
12. Clinical Trials.gov. Phase III Double-blind, Placebo-controlled study of AZD1222 for the prevention of COVID-19 in Adults. Available from URL: https://clinicaltrials.gov/ct2/show/NCT04516746
13. European Medicine Agency. EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca. Available from URL: https://www.ema.europa.eu/en/news/ema-receives-application-conditional-marketing-authorisation-covid-19-vaccine-astrazeneca
14. Centers for Disease Control and Prevention. Understanding mRNA COVID-19 Vaccines. Available from URL: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html
15. World Health Organization. What typers of COVID-19 vaccines are being developed? How would they work? Available from URL: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines?adgroupsurvey={adgroupsurvey}&gclid=EAIaIQobChMIot2JjNff7gIVxamWCh3T3QjqEAAYASAAEgKauPD_BwE
16. Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020;383:2439-50.
17. Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2 neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/ content/10.1101/2020.12.09.20245175v1). preprint.
18. Polack FP et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med 2020;383:2603-15. DOI: 10.1056/NEJMoa2034577
19. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. Available from URL: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
20. European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU. Available from URL: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu
21. European Medicines Agency. European Medicines Agency confirms no deaths have been linked to the Pfizer/BioNTech vaccine. Available from URL: https://www.thejournal.ie/pfizer-biontech-covid19-vaccine-deaths-europe-norway-ema-5339644-Jan2021/
22. Corbett KS et al. Evaluation of the mRNA-123 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020 Oct 15;383(16):1544-1555. doi: 10.1056/NEJMoa2024671
23. Jackson LA et al. An mRNA Vaccine against SARS-CoV-2- Preliminary Report. N Engl J Med.2020 Nov 12;383(20):1920-1931
24. Anderson EJ et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436
25. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
26. US Food and Drug Administration. Moderna COVID-19 Vaccine. Available from URL: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine
27. European Medicines Agency. COVID-19 Vaccine Moderna. Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna#authorisation-details-section
28. Sadoff J et al. Interim Results of a Phase1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021 Jan 13;NEJMoa2034201. doi: 10. 1056/ NEJMoa 2034201.
29. Fernandes A, Chaudhari S, Jamil N, Gopalakrishnan G. COVID-19 Vaccine [published online ahead of print, 2021 Jan 27].Endocr Pract. 2021;S1530-891X(21)00019-7. doi:10.1016/j.eprac.2021.01.013
30. National Institutes of Health. Janssen Investigational COVID-19 Vaccine: Inerim Analysis of Phase 3 Clinical Data Released. Available from URL: https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released
31. U.S Food and Drug Administration. FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine. Available from URL: https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine
32. NOVAVAX. Novavax COVID-19 Vaccine Demonstrates 89,3% Efficacy in UK Phase 3 Trial. Available from URL: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
33. Tian, JH., Patel, N., Haupt, R. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.Nat Commun 12, 372 (2021). https://doi.org/10.1038/s41467-020-20653-8
34. Keech C et al. Phase 1–2 Trial of a SARS CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med 2020; 383:2320-2332. DOI: 10.1056/NEJMoa2026920\
35. FiercePharma. AstraZeneca hopes warmer storage needs for COVID-19 vaccine will be an advantage against mRNA competitors. Available from URL: https://www.fiercepharma.com/manufacturing/astrazeneca-hopes-warmer-storage-needs-for-covid-19-vaccine-will-be-advantage-against
36. Johnson& Johnson. Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial. Available from URL: https://www.prnewswire.com/news-releases/johnson--johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial-301218035.html
37. Xie X et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera. bioRxiv 2021. 01.27. 427998 doi: https:// doi.org/10.1101/2021.01.27.427998
38. WHO. COVAX Statement on New Variants of SARS-CoV-2. Available from URL: https://www.who.int/news/item/08-02-2021-covax-statement-on-new-variants-of-sars-cov-2
39. Medscape. Sinovac Vaccine Works on UK, South African Variants: Brazil Institute. Available from URL: https://www. medscape. com/ viewarticle/945971.
40. Logunov DY et al. Safety and efficacy of an Ad26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.Lancet 2021;397:671-81. https://doi.org/10.1016/ S0140-6736(21)00234-8